Skip to main content
. 2024 Jul 26;15:1388753. doi: 10.3389/fphar.2024.1388753

FIGURE 2.

FIGURE 2

Efficacies of WWXDD on gout flare patients. (A) All patients achieved clinical remission in both groups. The complete response rate was 66% in the WWXDD group and 59% in the colchicine group, which showed no significant difference between the two groups (p = 0.642). (B) There were no significant differences in joint symptom scores on the 7th day between the two groups (p = 0.539). However, compared with the scores on the 1st day, there were significant improvements observed in both groups (WWXDD: 1st day vs. 7th day, 2(2-4) vs 0(0-1), p < 0.001; Colchicine: 1st day vs. 7th day, 2 (2–4.5) vs. 0 (0–1), p < 0.001). (C) Levels of C-reactive protein on the 7th day did not differ significantly between the WWXDD and colchicine groups (WWXDD vs colchicine, mean ± SD: 7.96 ± 13.97 vs. 6.65 ± 7.81, p =0 .71). However, when compared with levels on the first day, there were significant reductions observed in both groups (WWXDD: 1st day vs. 7th day, mean ± SD: 37 .11 ± 32 .20 vs. 7 .96 ± 13 .97, p = 0 .004; Colchicine: 1st day vs. 7th day, mean ± SD: 27 .33 ± 38 .57 vs. 6 .65 ± 7 .81, p = 0.008). WWXDD, WWXDD group; Colchicine, positive control group. * p < 0.05.